Wright Medical Technology Metal-on-Metal 522 Post-Market Surveillance Study

Post-Market Surveillance of the Wright Medical Technology Metal-on-Metal Total Hip System (FDA 522 Order)

This study is in response to the Food and Drug Administration (FDA) call to all manufacturers with 510(k) clearance for metal-on-metal (MoM) total hip arthroplasty (THA) devices to conduct postmarket surveillance studies. MicroPort has various acetabular shells, acetabular liners, fixation screws, femoral heads, femoral stems, modular necks, and proximal bodies currently cleared for MoM indications. Together these components comprise the Wright Medical Technology (WMT) MoM THA System. The primary objective of the study is to determine the incidence of adverse local tissue reactions (ALTR) in each THA implanted with the WMT MoM THA System overall and to create cross-sectional epochs of ≤ 8 years and > 8 years, since implantation.

Study Overview

• Status: Completed
• Conditions: Joint Pain; Osteoarthritis, Hip; Hip Osteoarthritis; Hip Disease
• Intervention / Treatment: Device: Wright Medical Technology Metal-on-Metal Total Hip System

• Study Type: Observational
• Enrollment (Actual): 173

Contacts and Locations

Study Locations

• United States
  • California
    • El Cajon, California, United States, 92020
      • Triwest Research Associates
    • La Mesa, California, United States, 91942
      • BioSolutions Research Center
  • Iowa
    • Iowa City, Iowa, United States, 52242
      • University of Iowa
  • Washington
    • Spokane, Washington, United States, 99208
      • Spokane Joint Replacement Center, Inc.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 21 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Group 1: Subjects previously implanted with components of the Wright Medical Technology (WMT) Metal-on-Metal (MoM) Total Hip Arthroplasty (THA) System

Group 2: Control, non-implanted subjects

Description

Inclusion Criteria:

To be included in Group 1, subjects must meet all of the following criteria:

1. Has been implanted with appropriate components of the WMT MOM THA System

2. Has previously undergone primary THA for any of the following:

   1. non-inflammatory degenerative joint disease including osteoarthritis, traumatic arthritis, or avascular necrosis;
   2. inflammatory degenerative joint disease including rheumatoid arthritis;
   3. correction of functional deformity.
3. Is willing and able to complete required study visit(s) and assessments
4. Plans to be available for the required study visit
5. Is capable of providing sufficient blood for sampling according to blood draw procedures
6. Is willing to sign the approved Informed Consent document

Previously implanted bilateral subjects can have both THAs enrolled in the study provided: 1) the specified combination of components were implanted in both, 2) all other aspects of the Inclusion/Exclusion Criteria are satisfied, 3) enrollment does not exceed the subject count specified in the Clinical Trial Agreement and protocol enrollment strategy, and 4) the subject agrees to a second Informed Consent document and data collection specific to the second THA. Enrollment and treatment of a previously unimplanted hip is not permitted in this study.

To be included in Group 2, subjects must meet all of the following criteria:

1. Does not have a metal implant (total hip, total knee, spinal, etc.) with the exception of dental implants
2. Is not an employee of the Investigator
3. Is willing and able to provide Informed Consent document
4. Is willing and able to attend the requested study visit(s) and assessments
5. Is capable of providing sufficient blood for sampling according to blood draw procedures

Exclusion Criteria:

Subjects will be excluded from either study group if they meet any of the following criteria:

1. Subject is currently enrolled in another clinical investigation which could affect the endpoints of this protocol
2. Subject is unwilling or unable to sign the Informed Consent document
3. Subject has documented substance abuse issues
4. Subject has an emotional or neurological condition that would pre-empt their ability or willingness to participate in the study
5. Subject is currently incarcerated or has impending incarceration
6. Group 1 only: Subject has a condition or previously implanted medical device that contraindicates MRI (e.g. pacemaker, implantable defibrillator)
7. Group 1 only: Subject was skeletally immature (less than 21 years of age) at time of implantation

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Cross-Sectional

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Previously Implanted (Group 1); Subjects previously implanted with components of the Wright Medical Technology (WMT) Metal-on-Metal (MoM) Total Hip Arthroplasty (THA) System	Device: Wright Medical Technology Metal-on-Metal Total Hip System; Subjects in Group 1 previously implanted prior to the study start date will be identified from Investigator records. Collected data will be evaluated in aggregate and cross-sectioned by year of implantation. Subjects will be cross-sectioned by the time that has elapsed between implantation and the initial visit (e.g. 5 years, 6 years) using contiguous visit windows (number of years + 6 months). Subject data will be grouped in order to create cross-sectional epochs of ≤ 8 years and > 8 years.
Control (Group 2); Control, non-implanted subjects

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Rate of Adverse Local Tissue Reactions (ALTR)	To determine the incidence rate of ALTR in subjects implanted with WMT MoM THA System (Group 1)	≤ 8 years and > 8 years, since implantation

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Determine chromium and cobalt whole blood and serum ion levels across time intervals	Cobalt and chromium metal ion levels will be measured in whole blood and serum from subjects implanted with the WMT MoM THA System (Group 1) at each defined cross-section interval.	≤ 8 years and > 8 years, since implantation
Establish baseline for chromium and cobalt whole blood and serum ion levels across time intervals	Analyze difference in chromium and cobalt whole blood and serum ion levels in subjects implanted with the WMT MoM THA System (Group 1) versus control subjects (Group 2) cross-sectionally.	≤ 8 years and > 8 years, since implantation
Compare functional outcomes of subjects implanted with the WMT MoM THA System with and without ALTR (Group-1 subjects).	Calculate and compare composite hip outcomes scores, via the validated HOOS scores, in Group 1 subjects with ALTR versus Group 1 subjects without ALTR	≤ 8 years and > 8 years, since implantation
Compare cobalt and chromium metal ion levels in subjects implanted with the WMT MoM THA System with and without ALTR (Group-1 subjects).	Analyze difference in cobalt and chromium metal ion levels from Group 1 subjects with ALTR versus Group 1 subjects without ALTR	≤ 8 years and > 8 years, since implantation

Collaborators and Investigators

• Sponsor: MicroPort Orthopedics Inc.

Study record dates

Study Major Dates

• Study Start (Actual): April 11, 2018
• Primary Completion (Actual): November 24, 2021
• Study Completion (Actual): June 18, 2022

Study Registration Dates

• First Submitted: February 23, 2018
• First Submitted That Met QC Criteria: February 28, 2018
• First Posted (Actual): March 1, 2018

Study Record Updates

• Last Update Posted (Actual): October 13, 2022
• Last Update Submitted That Met QC Criteria: October 12, 2022
• Last Verified: October 1, 2022

More Information

Terms related to this study

• Keywords: THA; Total Hip Arthroplasty; Metal-on-Metal; MOM
• Additional Relevant MeSH Terms: Pain; Neurologic Manifestations; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Arthritis; Osteoarthritis; Arthralgia; Osteoarthritis, Hip
• Other Study ID Numbers: 11LJH001

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: No